NASDAQ:UPC Universe Pharmaceuticals Q2 2026 Earnings Results & Report $4.15 -0.03 (-0.72%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$4.21 +0.06 (+1.47%) As of 10/9/2026 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Universe Pharmaceuticals reported Q2 2026 earnings on July 29, 2026. The company reported EPS of -$1.38, while revenue was $4.52 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateJuly 29, 2026TimeAfter Market Closes Universe Pharmaceuticals EPS ResultsActual EPS-$1.38Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AUniverse Pharmaceuticals Revenue ResultsActual Revenue$4.52 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Universe Pharmaceuticals Q2 2026 Earnings FAQ Did Universe Pharmaceuticals beat earnings estimates for Q2 2026? Universe Pharmaceuticals (NASDAQ:UPC) reported earnings of -$1.38 per share for Q2 2026. The report was announced on Wednesday, July 29, 2026. What was Universe Pharmaceuticals' revenue for Q2 2026? Universe Pharmaceuticals reported revenue of $4.52 million for Q2 2026. Universe Pharmaceuticals Earnings HeadlinesThe Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC. (UPC) on Behalf of InvestorsOctober 7, 2026 | tmcnet.comThe Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC.October 7, 2026 | businesswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 11 at 1:00 AM | Altimetry (Ad)Universe Pharmaceuticals shares rise 22.6% premarket with no new catalyst identifiedSeptember 2, 2026 | msn.comUniverse Pharmaceuticals (UPC) stock soars over 38% after-hours: Here's what's going onSeptember 2, 2026 | msn.comUniverse Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:UPCJuly 18, 2026 | benzinga.comSee More Universe Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Universe Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Universe Pharmaceuticals and other key companies, straight to your email. Email Address About Universe PharmaceuticalsUniverse Pharmaceuticals (NASDAQ:UPC). (NASDAQ: UPC) is a China-based pharmaceutical company engaged in the development, manufacture and sale of traditional Chinese medicine (TCM) products and other healthcare offerings. The company serves consumers primarily through pharmaceutical distributors, retail pharmacies and other sales channels in China. Universe Pharmaceuticals’ product portfolio includes over-the-counter and prescription pharmaceutical products, as well as healthcare and nutritional products. Its offerings are derived in part from traditional Chinese medicine formulations and are intended to address a range of consumer health needs. The company also provides related product distribution and marketing services. Founded in 1998, Universe Pharmaceuticals is headquartered in Xi’an, Shaanxi Province, China. Its operations and primary market are concentrated in mainland China. The company completed its initial public offering on the Nasdaq Capital Market in 2021.View Universe Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
